IL2 and neoplasm: Given the rapid development of tumor immunology, a large number of previous studies had found that traditional immunotherapy, such as IFN-α and IL-2, could extend the OS to a certain extent, but their response duration was limited, and only a few patients could fully respond (Floros and Tarhini, 2015; Mao et al., 2021b).